Viewing nowCombinationSitamepo Tablets 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Youngil Pharmaceutical Co., Ltd.

MFDS item code 202200198 · Approved 2022.01.11 · Insurance code 649405650
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise therapy to help patients with type 2 diabetes control their blood sugar. It is administered as monotherapy for patients who are new to diabetes medication and are not achieving adequate blood sugar control. Additionally, it may replace metformin or sitagliptin monotherapy when blood sugar control is difficult, or when both medications are used together. If blood sugar control is still insufficient despite combination therapy with metformin and sulfonylurea or thiazolidinedione, this medication can be added. If blood sugar control remains challenging with insulin and metformin combination therapy, this medication can be used together with insulin. It is therefore effective in improving blood sugar control under various circumstances.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2. Patients who must not take this medicine under Precautions for Use). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see section 5. General Precautions under Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Patients who must not take this medicine under Precautions for Use).
This medication contains sitagliptin and metformin and is used to treat diabetes. First, this medication may cause allergic reactions; if symptoms such as rash, hives, or difficulty breathing occur, you should stop using it immediately and consult a physician. Acute pancreatitis, a serious inflammation of the pancreas, may rarely occur, so if you experience abdominal pain, vomiting, or severe abdominal discomfort, you should inform a healthcare provider immediately. Furthermore, the metformin component may rarely cause a serious metabolic disturbance known as lactic acidosis, so if you experience shortness of breath, severe muscle pain, fatigue, or abdominal pain, you must go to the hospital immediately. This medication should not be administered to patients with severely impaired kidney function, acute heart failure, serious infections, severe liver disease, or to women who are pregnant or breastfeeding. Particularly in cases of compromised kidney function, administration of this medication should be avoided or done with caution, and regular kidney function tests must be performed. Additionally, excessive alcohol consumption should be avoided during treatment; and if surgery is imminent, the medication should be stopped 48 hours prior to the surgery and can be resumed only after confirming normal kidney function post-surgery. This medication poses a risk of hypoglycemia, so regular meals should be maintained, and caution should be exercised during vigorous exercise or if food intake is insufficient. When used in combination with other blood sugar-lowering agents, especially insulin or sulfonylureas, the risk of hypoglycemia increases, so dosages should be adjusted according to a physician's directions. Regular blood sugar, kidney function, and blood tests should be conducted during the use of this medication to monitor for abnormalities, and vitamin B12 levels may decrease, so supplementation may be necessary. Finally, this medication has not established safety and efficacy in children and adolescents; therefore, it should not be used in this demographic. By adhering to these precautions, the benefits of this medication can be enjoyed safely.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture. Additionally, avoid storing in extremely hot or cold places; it is recommended to store it at room temperature between 1 degree and 30 degrees Celsius.
Light pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Youngil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.